High-Level Overview
Clue by Biowink is a Berlin-based femtech company that develops the leading period and cycle tracking app, available on iOS, Android, and Apple Watch, serving over 10 million active users worldwide.[1][2][3] It empowers women and people with cycles to understand their biology through data-driven predictions of periods, PMS, fertility windows, and symptoms, while prioritizing data privacy and scientific accuracy; its mission is to enable informed choices and fuller lives in tune with biology.[1][2] The app solves the knowledge gap in menstrual health by offering free core features plus Clue Plus—a €1/month subscription for personalized forecasts—and addresses specific needs like conception, perimenopause, birth control piloting, and health conditions to close diagnosis gaps.[2][3][4] Backed by investors including Union Square Ventures, Mosaic Ventures, and Groupe Arnault, Clue has shown strong growth, reaching 3 million monthly active users early on, achieving CE marking as a Class 1 medical device, and conducting major studies with partners like the Bill & Melinda Gates Foundation.[1][3]
Origin Story
Clue was co-founded in 2012 (with app launch in 2013) in Berlin by Danish entrepreneur Ida Tin, alongside Hans Raffauf, Moritz von Buttlar, and Mike LaVigne; Ida, inspired by her own struggles with birth control side effects as a former motorcycle guide, envisioned technology transforming family planning and women's health.[1][2][3][4] The idea emerged from Ida's conviction that serious, empathetic tools were needed to track and demystify menstrual cycles, leading her to pioneer the "femtech" category to legitimize and attract investment in female health tech.[3][4] Early traction included iOS launch in 2013, Android in 2014, a €500k seed round, and rapid user growth to 3 million monthly actives; pivotal moments featured Series A funding, media acclaim from TechCrunch and Wired, and expansions like helloclue.com in 2018 for science-backed education.[1][2][3]
Core Differentiators
- Scientific Rigor and Accuracy: Rated #1 by Obstetrics & Gynecology journal, tracks 31 categories (e.g., pain, PMS, sleep, exercise), uses the world's largest menstrual dataset for precise predictions, and pairs app data with surveys for research like COVID-19 cycle impacts and heavy menstrual bleeding studies with Gates Foundation.[3][4]
- Privacy and Accessibility: Emphasizes secure, private data handling; free app with affordable Clue Plus (€1/month equivalent globally) for enhanced analysis, plus specialized tools like Clue Conceive, Perimenopause, and Health Conditions features.[1][2][3]
- Educational Ecosystem: helloclue.com provides accessible, evidence-based menstrual info; thought leadership in femtech via partnerships with Kinsey Institute, Stanford, Oxford, and record equity crowdfund (5,000+ investors, 85% female).[1][3][4]
- User-Centric Evolution: Recent redesign, CE-marked medical device status, and leadership shift to CEO Audrey Tsang; doctor-recommended with global praise for empathy and innovation.[1][2][3]
Role in the Broader Tech Landscape
Clue rides the femtech wave, defining and expanding a category for tech addressing underserved women's reproductive health amid rising demand for personalized, data-driven wellness tools.[3][4] Timing aligns with growing awareness of menstrual research gaps, post-COVID health tracking needs, and VC interest spurred by Clue's successes like academic partnerships and Gates Foundation studies, which leverage its massive dataset to advance global female health equity.[3][4] Market forces favoring Clue include app store dominance, privacy regulations boosting trust, and cultural shifts toward body literacy; it influences the ecosystem by inspiring femtech investments, conferences, and products while contributing anonymized data for disease detection and myth-busting.[1][3][4]
Quick Take & Future Outlook
Clue is poised to deepen its medical device role with expansions in AI-enhanced predictions, perimenopause support, and diagnosis tools, potentially scaling via global partnerships and its dataset's research value.[3] Trends like femtech maturation, wearable integrations (e.g., Apple Watch), and equity-driven funding will propel growth, evolving Clue from tracker to comprehensive reproductive health platform under CEO Audrey Tsang.[3] As the #1 app with 10M+ users, its influence could redefine family planning, tying back to Ida Tin's vision of tech empowering biology.[1][4]
